Pharmaceutical giant Adcock Ingram has announced flat annual profits despite a significant recovery in the second half of its financial year. This was buoyed by strong demand for its popular over-the-counter winter medicines. In a landmark move, the maker of household staples like Panado and Corenza-C is also set to delist from the Johannesburg Stock Exchange (JSE). This follows a…